Clinical Trial Update: Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer. [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating pembrolizumab in combination with guadecitabine and mocetinostat for advanced lung cancer; status indicates active but not rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer

Drugs mentioned

• Mocetinostat (mocetinostat)
• Pembrolizumab (pembrolizumab)
• SGI-110 (guadecitabine)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Lung Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING